Immunology Program

The Andrea Schietinger Lab


Andrea Schietinger
Andrea Schietinger, PhD
Member, Immunology Program, SKI; Catherine and Frederick R. Adler Chair for Junior Faculty

The goal of our laboratory is to understand when, why, and how immune cells become unresponsive to tumors or self-destructive in autoimmune diseases. We develop genetic cancer mouse models that mimic cancer development in patients, investigate T cell responses over the course of tumor development, and define the molecular mechanisms that are responsible for the failure to control and eliminate tumors. In addition, we utilize clinically relevant mouse models of autoimmunity, such as Type 1 Diabetes, to understand how autoimmune responses are initiated and sustained. Our ongoing and future research programs aim to develop a deep mechanistic understanding of the spatiotemporal, molecular, and epigenetic factors that determine T cell fate decisions and functional/dysfunctional states in cancer and autoimmunity, and test innovative conceptual frameworks and T cell reprogramming approaches for the treatment of T cell-mediated diseases. Detailed information about our research is available at

Andrea Schietinger lab

Publications Highlights

Gearty SV, Dündar F, Zumbo P, Espinosa-Carrasco G, Shakiba M, Sanchez-Rivera F, Socci ND, Trivedi D, Lowe SW, Lauer P, Mohibullah N, DiLorenzo TP, Viale A, Betel D, Schietinger A. A stem-like autoimmune CD8 T cell population drives type 1 diabetes. Nature 2022 Feb;602(7895):156-161.

Shakiba M, Zumbo P, Dündar F, Espinosa-Carrasco G, Camara S, Sanchez-Rivera FG, Lowe SW, Koche RP, Reuter VP, Socci ND, Whitlock B, Tamzalit F, Huse M, Betel D, Philip M, Schietinger A. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. Journal of Experimental Medicine 2022 Feb 7;219(2):e20201966.

Philip M and Schietinger A. CD8 T cell differentiation and dysfunction in cancer. Nature Reviews Immunology. 2022 Apr;22(4):209-223.

View All Publications


Andrea Schietinger

Andrea Schietinger, PhD

Member, Immunology Program, SKI; Catherine and Frederick R. Adler Chair for Junior Faculty

  • Cancer Immunologist Andrea Schietinger investigates immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy.
  • PharmD, University of Hamburg, PhD, University of Chicago, Chicago, IL and University of Munich, Germany
  • Postdoctoral Training: Fred Hutchinson Cancer Research Center and University of Washington, Seattle
[email protected]
Email Address
Office Phone


Andrea Schietinger, PhD
Andrea Schietinger

Principal Investigator, Associate Member

Dave Asim

Research Assistant

Sufia Bakshi

IMP MD/PhD Student

Sandra Carson

BCMB PhD Student

Edison Chiu

Lab Manager

Sofia Dimitriadoy

IMP MD/PhD Student

Katrina Hawley

PhD - Postdoctoral Fellow

Nadine  Hernandez
Nadine Hernandez

Senior Administrative Assistant

Ian McBain

IMP PhD Student

Laura Menocal
Laura Menocal

IMP PhD Student

Svetlana Miakicheva

IMP PhD Student

Brianna Naizir
Brianna Naizir

GSK PhD Student

Joseph Palmeri

PhD - Postdoctoral Fellow

Lab Alumni
Varintra Krisnawan

Research Technician

Mary Philip, MD PhD
Mary Philip

Senior Research Scientist

Nayanta Buchanan
Nayanta Buchanan

Administrative Assistant

Heather Appleby, Research Technician
Heather Appleby

Research Technician

Steven  Camara
Steven Camara
Gabriel Espinosa-Carrasco
Gabriel Espinosa-Carrasco

Postdoctoral Fellow

Sofia Vaccarino Gearty
Sofia Vaccarino Gearty

MD, PhD Student

Ellen  Horste
Ellen Horste

Research Scientist

Andrew Scott
Andrew Scott

PhD Student

Mojdeh  Shakiba
Mojdeh Shakiba

PhD Student

Prerak Trivedi, Research Fellow
Prerak Trivedi

Postdoctoral Fellow

Lab Affiliations


  • AACR-Irving Weinstein Foundation Distinguished Lectureship Award (2023)
  • American Association of Immunologists - AAI BD Biosciences Investigator Award (2022)
  • AACR-Bristol Myers Squibb Midcareer Female Investigator Award (2021)
  • Catherine and Frederick R. Adler Chair for Junior Faculty (2021)
  • Louise and Allston Boyer Young Investigator Award for Basic Research (2020)
Read more
  • Pershing Square Sohn Award (2020)
  • Josie Robertson Investigator (2014-2019)
  • Cancer Research Institute Lloyd Old STAR Award (2019)
  • NIH Director’s Innovator Award (2017)
  • NIH/NCI K99/R00 Award (2015)
  • V Foundation for Cancer Research Award (2015)
  • William and Ella Owens Medical Research Foundation Award (2016)
  • Cancer Research Institute Irvington Fellowship (2012)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Tumor Immunology

Apply now

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrea Schietinger discloses the following relationships and financial interests:

  • Centro Nacional de Investigaciones Oncológicas
    Professional Services and Activities (Uncompensated)
  • KU Leuven
    Professional Services and Activities (Uncompensated)
  • Keystone Symposia
    Professional Services and Activities (Uncompensated)
  • Ludwig Maximilian University of Munich
    Professional Services and Activities (Uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures